$GILD News Cypress, Spansion shares rally on merger

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
$GILD News

Cypress, Spansion shares rally on merger plan 5:36 p.m. Dec. 1, 2014 - MarketWatch
Mylan to manufacture, distribute Gilead Sciences HIV drug 7:49 a.m. Dec. 1, 2014 - Angela Chen
10 stocks that may revisit their highs as the year ends 10:30 a.m. Nov. 24, 2014 - Philip van Doorn
Are consumers getting gouged on health care? 9:35 a.m. Nov. 22, 2014 - Russ Britt
Gilead Sciences shares slide 1.7% 9:35 a.m. Nov. 19, 2014 - Sue Chang
The double-edged sword of growth-stock speculation 2:29 p.m. Nov. 14, 2014 - The Trading Deck
10 S&P 500 companies with the fastest revenue growth 8:28 a.m. Nov. 11, 2014 - Philip van Doorn
Merck, Dendreon miss out on health-care rally 12:39 p.m. Nov. 10, 2014 - Russ Britt
Gilead Sciences rises 2% to top S&P 500 gainers 9:31 a.m. Nov. 10, 2014 - Sue Chang
Visa shares rise after hours on earnings beat 6:50 p.m. Oct. 29, 2014 - Sue Chang
Warren Buffett best wear his trunks as Fed preps to end (pause) the printing 8:34 a.m. Oct. 29, 2014 - Shawn Langlois
Facebook, Gilead shares fall after hours 6:14 p.m. Oct. 28, 2014 - Sue Chang
Updates, advisories and surprises 5:01 p.m. Oct. 28, 2014 - MarketWatch
Sales of Gilead's pricey hepatitis C drug slow 4:26 p.m. Oct. 28, 2014 - MarketWatch.com
Gilead Sciences' stock pulls back from record high close after earnings miss 4:14 p.m. Oct. 28, 2014 - Tomi Kilgore
Gilead's stock drops 3.6% in after-hours trade after Q3 results 4:09 p.m. Oct. 28, 2014 - Tomi Kilgore
Gilead revises 2014 product sales outlook to $22 bln-$23 bln from $21 bln-$23 bln 4:08 p.m. Oct. 28, 2014 - Tomi Kilgore
Gilead Q3 Sovaldi sales $2.8 bln vs. $3.48 bln in Q2 4:07 p.m. Oct. 28, 2014 - Tomi Kilgore
Gilead Q3 sales top FactSet consensus estimate of $5.99 bln 4:07 p.m. Oct. 28, 2014 - Tomi Kilgore
Gilead Q3 sales $6.04 bln vs. $2.78 bln a year ago 4:07 p.m. Oct. 28, 2014 - Tomi Kilgore


Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan 8:22 p.m. Dec. 5, 2014 - TheStreet.com
Why Gilead Is A Better Buy Than AbbVie 2:52 p.m. Dec. 5, 2014 - Seeking Alpha
Cramer Says It May Finally Be Time to Buy Laggard Gilead Sciences 12:18 p.m. Dec. 5, 2014 - TheStreet.com
Gilead Sciences Spikes Higher As Barron's Suggests Looking Beyond Hepatitis-C 9:50 a.m. Dec. 5, 2014 - benzinga.com
'Mad Money' Lightning Round: Buy, Buy, Buy Texas Instruments 6:00 a.m. Dec. 5, 2014 - TheStreet.com
Cramer's Lightning Round - Constellation Brands Has Real Magic (12/4/14) 4:36 a.m. Dec. 5, 2014 - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: Google Is Better Than the Market Thinks 8:31 p.m. Dec. 4, 2014 - TheStreet.com
Hot Drugmakers Build More Labs, Grab Space In Boston 3:47 p.m. Dec. 4, 2014 - Investors Business Daily
Gilead Sciences: An Alpha Stock Through The Good And Bad Times 3:14 p.m. Dec. 4, 2014 - Seeking Alpha
A Practical Approach To Tech Investing 9:00 a.m. Dec. 4, 2014 - Seeking Alpha
U.S. Veterans get Sovaldi for $594/pill 8:43 a.m. Dec. 4, 2014 - Seeking Alpha
Cramer's Mad Money - PVH Fits Well At A Discount (12/3/14) 6:04 a.m. Dec. 4, 2014 - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: Cyclical Stocks Are Fund Manager Picks Now 8:36 p.m. Dec. 3, 2014 - TheStreet.com
Third Quarter Earnings Season In Review: Sector Winners And Losers, The Misleading 'Record' Beat Rate And The Outlook For Q4 5:50 p.m. Dec. 3, 2014 - Seeking Alpha
Actelion submits MAA for pulmonary hypertension drug 3:36 p.m. Dec. 3, 2014 - Seeking Alpha
Gilead Sciences' (GILD) Management Presents at Piper Jaffray Healthcare Conference (Transcript) 11:53 a.m. Dec. 3, 2014 - Seeking Alpha
Mylan, Gilead Ink Deal for TAF-based HIV Drugs - Analyst Blog 5:45 p.m. Dec. 2, 2014 - Zacks.com
Apple, Facebook: Jason Weiner Of Fidelity's View 5:19 p.m. Dec. 2, 2014 - Investors Business Daily
An Update For Gilead Sciences 4:32 p.m. Dec. 2, 2014 - Seeking Alpha
Gilead Set To Trounce AbbVie's HCV Combo 11:29 a.m. Dec. 2, 2014 - Seeking Alpha


Reveal Earnings Forecast for Gilead Sciences, Kinder Morgan, JD.Com, Sirius XM, Apple, and Plug Power 8:45 a.m. Dec. 4, 2014 - PR Newswire - PRF
Earnings Forecast Reports for Apple, Alibaba, Kinder Morgan, Gilead Sciences, Plug Power, and Yahoo 8:45 a.m. Dec. 2, 2014 - PR Newswire - PRF
Mylan Signs Agreement with Gilead to Enhance Access to Tenofovir Alafenamide (TAF)-based HIV Treatments in Developing Countries 7:00 a.m. Dec. 1, 2014 - PR Newswire - PRF
Reveal Earnings Forecast for Apple, Alibaba, Hewlett-Packard, Gilead Sciences, Petrobras, and BlackBerry 8:45 a.m. Nov. 26, 2014 - PR Newswire - PRF
Critical Alerts For SouFun, Petroleo Brasileiro, Gilead Sciences, Transocean and iRobot Released By InvestorsObserver 9:31 a.m. Nov. 24, 2014 - PR Newswire - PRF
Earnings Forecast Research for Kinder Morgan, Petrobras, Freeport-McMoRan, Keurig Green Mountain, Gilead Sciences, and Alibaba 8:45 a.m. Nov. 24, 2014 - PR Newswire - PRF
Earnings Forecast Report for Yahoo, Alibaba, Cliffs Natural Resources, Gilead Sciences, Apple, and Plug Power 8:45 a.m. Nov. 20, 2014 - PR Newswire - PRF
Knight Sells Priority Review Voucher to Gilead 5:11 p.m. Nov. 19, 2014 - Marketwired
European Commission Grants Marketing Authorization for Gilead’s Harvoni®▼ (Ledipasvir/Sofosbuvir), the First Single Tablet Regimen to Treat the Majority of Chronic Hepatitis C Patients With Genotype 1 and 4 10:07 a.m. Nov. 18, 2014 - BusinessWire - BZX
Earnings Forecast Buzz for Baker Hughes, Halliburton, Apple, Gilead Sciences, Kinder Morgan, and Alibaba 8:45 a.m. Nov. 18, 2014 - PR Newswire - PRF
Equity Coverage on Biotech Industry - Gilead Sciences, MannKind, ARIAD Pharma, iBio Inc., and Celgene 9:10 a.m. Nov. 14, 2014 - PR Newswire - PRF
Reveal Earnings Forecast for BlackBerry, Twitter, Alibaba, Sirius XM, Gilead Sciences, and JD.Com 8:45 a.m. Nov. 14, 2014 - PR Newswire - PRF
Gilead Prices $4 Billion of Senior Unsecured Notes 5:59 p.m. Nov. 12, 2014 - BusinessWire - BZX
Earnings Forecast Recap for Alibaba, Apple, Zynga, Gilead Sciences, Dendreon, and Juniper 8:45 a.m. Nov. 12, 2014 - PR Newswire - PRF
Gilead Announces Phase 2 Data for Investigational All-Oral Regimen of Sofosbuvir Plus GS-5816 for the Treatment of Chronic Hepatitis C 8:02 a.m. Nov. 11, 2014 - BusinessWire - BZX
Gilead Announces Harvoni Study Results in Chronic Hepatitis C Patients with Advanced Liver Disease and Those Who Failed Prior Treatment 8:02 a.m. Nov. 11, 2014 - BusinessWire - BZX
Earnings Forecast Buzz for Alibaba, Genworth Financial, Gilead Sciences, Zynga, Abercrombie & Fitch, and Plug Power 8:45 a.m. Nov. 10, 2014 - PR Newswire - PRF
Medifocus to Be Broadcast on BNN and Fox Business News on November 8th and 9th, 2014 10:56 a.m. Nov. 7, 2014 - Marketwired
Linkage Biosciences Adds to Board Leadership 8:02 a.m. Nov. 7, 2014 - Marketwired
Critical Alerts For Delta Airlines, ConocoPhillips, Qualcomm, Kinder Morgan and Gilead Sciences Released By InvestorsObserver 9:31 a.m. Nov. 6, 2014 - PR Newswire - PRF

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Love Business Group Helps SMEs Navigate Broadband Choices

Updated Category News Views 136

Understanding Broadband Needs for UK SMEs When you're knee-deep in running a small biz in the UK, sorting out your broadband needs can feel like sifting through a thousand-piece puzzle. Enter Love Business Group, getting a nod of recognition for being the SME knight in shining armor. Aimed at businesses of all sizes, they've been pegged by Expert Consumers for helping...

Continue Reading
TORRAS Cases Balance Protection with Slim Design for 2026

Updated Category News Views 218

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...

Continue Reading
Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 337

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading
CapCut's Role in AI-Assisted Small Biz Marketing

Updated Category News Views 288

In today's fast-paced digital world, small businesses lament the constant hustle to stay relevant online. This juggling act with limited resources often makes effective marketing feel like a high-wire circus performance. Enter AI tools, promising to lighten the load, and CapCut stands out as a game-changer. AI Tools Revolutionizing Small Business Marketing Amid growing...

Continue Reading
Ping An's Bold Green Moves Ahead of APEC 2026

Updated Category News Views 201

Ping An's Pitch for Green: Talking the Talk and Walking the Walk? Well, here's something cooking in Shenzhen at the Ping An Finance Center—an international seminar championing green development initiatives. It's all buzz around Ping An Insurance (HKEX: 2318; SSE: 601318) flexing its green muscle, orchestrating conversations right before APEC 2026. Talk about timing....

Continue Reading
Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

Updated Category News Views 531

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Continue Reading
Tennessee's Bold Lung Cancer Trial Signals Innovation

Updated Category News Views 161

The Heartbeat of Innovation in Cancer Therapy Who would've thought Tennessee would be at the forefront of a global push against lung cancer? Sure, there's Nashville's music scene, but it's the researchers at Tennessee Oncology who are grooving to a different beat—one that might just set the rhythm for advanced cancer therapies worldwide. Yeah, it's a trial, but not just...

Continue Reading
Dr. Boonipat Inspires Future Women Surgeons at Texas Tech

Updated Category News Views 97

Sowing Surgical Seeds in Lubbock In Lubbock, Texas, something meaningful unfolded—an event the big market players would hardly blink at, but a significant step for the future of medicine. Led by Dr. Thanapoom "Mo" Boonipat, the founder of FacePlus Plastic Surgery Institute, a unique suturing workshop provided premed students at Texas Tech University hands-on experience...

Continue Reading
D-Wave Investors Must Decide by Dec 15 Class Suit

Updated Category News Views 117

Facing the Class Action Deadline There's nothing like a looming deadline to stir the pot, and that's exactly what's happening with D-Wave Quantum Inc. (NASDAQ: QBTS) as it faces the heat of a class action lawsuit. Investors who got caught in the slide between February 26, 2026, and August 25, 2026, need to sharpen their pencils and mark December 15, 2026, on their...

Continue Reading
Hims & Hers Faces FTC Heat: Investor Class Action Looms

Updated Category News Views 206

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

Continue Reading

Top 5 Most Recently Viewed Articles

Discover the Enhanced Features of the New ONYX RX32 Scrubber

Updated Category News Views 116

Introducing the New RX32 Ride-On Floor Scrubber Optimal Performance for Large-Area Cleaning In response to the growing need for effective cleaning solutions, ONYX Systems, LLC launches the advanced RX32 Ride-On Floor Scrubber. This 32-inch scrubber is designed specifically to enhance cleaning efficiency and productivity in large facilities. Unmatched Cleaning Power The...

Continue Reading
Deckers Outdoor Achieves Record Stock Price Amid Growth

Updated Category News Views 253

Deckers Outdoor Corporation Reaches New Stock Milestone Deckers Outdoor Corporation (NYSE: DECK), known for its exceptional footwear and apparel offerings, has achieved a remarkable milestone as its stock price climbs to an all-time high of $213.03. This impressive rise is indicative of the company's strong financial health and robust market performance. With a...

Continue Reading
Remarkable Growth in Badger Meter's Financial Performance

Updated Category News Views 76

Badger Meter's Impressive Q3 2024 Financial Results Badger Meter, Inc. (NYSE: BMI) has recently reported its remarkable financial outcomes for the third quarter that ended on September 30, 2024. The company has recorded impressive growth across its various financial metrics, indicating strong market demand and operational excellence. Key Highlights of Q3 2024 The latest...

Continue Reading
Perion Network's Collaboration with Experian Boosts Ad Targeting

Updated Category News Views 242

Perion Network Partners with Experian to Enhance Ad Solutions Perion Network (NASDAQ: PERI), a leading figure in the digital advertising technology sector, is taking a significant step forward with its collaboration with Experian, a renowned global data and analytics company. This strategic partnership aims to enhance Perion's advertising capabilities, focusing on...

Continue Reading
Novo Nordisk Investors Seek Class Action Guidance Following Lawsuit

Updated Category News Views 213

Insights into the Novo Nordisk Class Action Lawsuit Recent news has surfaced regarding Novo Nordisk A/S (NYSE: NVO), a major player in the global pharmaceutical industry, which is making headlines following the announcement of a class action lawsuit. This legal action is spearheaded by Berger Montague, a notable law firm based in various cities across the United States,...

Continue Reading